SCHEMBL17100616

SCHEMBL17100616

Cc1ccc(CN2CCN(c3nc(-c4ccccc4)no3)CC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.67
▸ ALDH1A1 P00352 5/20 0.67
▸ MAPT P10636 5/20 0.67
▸ SMN1; SMN2 Q16637 5/20 0.67
▸ TSHR P16473 3/20 0.67
▸ HSD17B10 Q99714 1/20 0.67
▸ CYP2D6 P10635 1/20 0.60
▸ KCNH2 Q12809 1/20 0.60
▸ POLB P06746 1/20 0.55
▸ HTT P42858 2/20 0.52
▸ USP2 O75604 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ CASP1 P29466 1/20 0.49
▸ CASP7 P55210 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100583 0.91 CYP2D6 (0.71) LMNAALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL17100630 0.89 SMN1; SMN2 (0.59) LMNAALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL17100781 0.87 MAPT (0.51) LMNAALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL17100591 0.83 MAPT (0.58) LMNAALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL17115008 0.83 KMT2A (0.55) LMNAALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL17100655 0.82 MAPT (0.66) LMNAALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL17100762 0.81 CYP2D6 (0.57) LMNAALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL17100737 0.81 ALDH1A1 (0.55) LMNAALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL17100584 0.81 KDM4E (0.58) LMNAALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL17100714 0.81 CYP2D6 (0.51) LMNAALDH1A1MAPTSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 — — US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 — — US claimed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 — — EP claimed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 — — WO claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 — — US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 — — US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 — — US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 — — US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 — — US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 — — US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 — — US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 — — EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 — — WO disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT LMNA 760/4885ALDH1A1 482/4885MAPT 3/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT LMNA 748/4885ALDH1A1 561/4885MAPT 3/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT LMNA 760/4885ALDH1A1 482/4885MAPT 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback